Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Vs-5584. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 13/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 7/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 5/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 3/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vs-5584 SCHEMBL29376859 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL3654994 | 0.89 | PIK3CA (0.81) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL539256 | 0.88 | PIK3CA (0.78) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL3791135 | 0.87 | PIK3CA (0.77) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7902204 | 0.86 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL31237219 | 0.86 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7908617 | 0.86 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7895963 | 0.86 | PIK3CA (0.76) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL20690791 | 0.85 | PIK3CA (0.74) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL7900637 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3R1MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | SOVARGEN CO., LTD. (KR) | 2025-10-28 | — | — | US | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| US-11304939-B2 | Methods for treating oral cancers | CHANG GUNG UNIVERSITY (TW) | 2022-04-19 | — | — | US | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO., LTD. (KR) | 2021-06-24 | — | — | US | claimed |
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| EP-3007556-A2 | CELL STABILIZATION | Biomatrica, INC. (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015002729-A2 | CELL STABILIZATION | BIOMATRICA, INC. (US) | 2015-01-08 | — | — | WO | claimed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| EP-2414362-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO Pte Ltd (SG) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114484-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114484-A1 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | S*BIO PTE LTD (SG) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | PIK3CA 2464/4885PIK3R1 3300/4885MTOR 4065/4885 |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | PIK3CA 347/4885PIK3R1 61/4885MTOR 1/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CA 2438/4885PIK3R1 3074/4885MTOR 4538/4885 |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | PIK3CA 358/4885PIK3R1 150/4885MTOR 1/4885 |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PIK3CA 264/4885PIK3R1 30/4885MTOR 147/4885 |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | MTOR, MAPKAP1, RPTOR | PIK3CA 358/4885PIK3R1 150/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.